UB-421 + antiretroviral therapy

UB-421 + antiretroviral therapy is a combination regimen in which **UB-421**, a humanized monoclonal antibody targeting CD4, is administered alongside **antiretroviral therapy (ART)** for the treatment of HIV-1 infection, particularly in patients with multidrug-resistant HIV or ART-stabilized patients. UB-421 is an Fc-aglycosylated, non-T cell depleting IgG1 antibody that binds with high affinity to domain 1 of the CD4 molecule on human lymphocytes, competitively inhibiting HIV entry and viral replication. It is designed to block HIV from binding to CD4+ T cells and prevents new infections, with additional immunomodulatory effects including reducing CD4 regulatory T cells and increasing HIV-specific CD8+ T cells. Combination therapy aims to achieve durable viral suppression, reduce latent HIV reservoirs, and potentially contribute to a functional cure of HIV. UB-421 + ART is being investigated in phase 2 clinical trials for efficacy and safety in patients with failing or multidrug-resistant ART regimens[1][2][3][4][5][6][7][8].

Brand names

UB-421UB421UB 421

Other names

UB-421 + ARTanti-CD4 antibody UB-421 plus antiretroviral therapyanti-CD-4 antibody UB-421 plus antiretroviral therapyanti-CD 4 antibody UB-421 plus antiretroviral therapy